论文部分内容阅读
目的:探讨进展期乳腺癌新辅助化疗的临床意义.方法:200001/200412应用CEF方案对86例ⅡbⅢ期乳腺癌患者进行新辅助化疗.环磷酰胺(CTX)500mg/m2,d1,d8;表阿霉素(EPI)50mg/m2,d1,d8;氟尿嘧啶(5Fu)500mg/m2,d1,d8.28d为1个周期,所有患者完成2个周期新辅助化疗后评价疗效.结果:35例(40.7%)降低了临床分期;4例(4.7%)获得完全缓解(CR),37例(43.0%)部分缓解(PR),全组无疾病进展(PD)者,总有效率(CR+PR)为47.7%(43/86).新辅助化疗2个周期后有24例(28.9%)未触及肿大淋巴结,腋窝淋巴结总有效率为61.4%(51/83).副反应为白细胞下降、恶心呕吐和脱发等,患者均可耐受.结论:进展期乳腺癌新辅助化疗对原发肿瘤和腋窝淋巴结均有较好疗效,不良反应可耐受,值得推广.
Objective: To investigate the clinical significance of neoadjuvant chemotherapy in advanced breast cancer.Methods: 200001/200412 Neonadjuvant chemotherapy was given to 86 patients with stage Ⅱb Ⅲ breast cancer using CEF regimen.Cyclophosphamide (CTX) 500mg / m2, d1, d8 All patients completed two cycles of neoadjuvant chemotherapy to evaluate the efficacy.Results: In 35 cases (50 cases in each group), EPI 50 mg / m2, d1, d8 and 5Fu in 500 mg / m2 for d1 and d8.28d, 40.7%) reduced the clinical stage; 4 patients (4.7%) achieved complete remission (CR), 37 patients (43.0%) partially relieved (PR), all patients without disease progression ) Were 47.7% (43/86) .There were 24 cases (28.9%) of untreated neoplasms after neoadjuvant chemotherapy, and the total effective rate of axillary lymph nodes was 61.4% (51/83) .The side effects were leukopenia, Nausea and vomiting and hair loss, patients can tolerate.Conclusion: Neoadjuvant chemotherapy for advanced breast cancer on the primary tumor and axillary lymph nodes have a good effect, adverse reactions are tolerable, it is worth promoting.